The biotech sector has fallen on hard times, with momentum investors fleeing the space and those who remain taking a much more careful look at just how much they are willing to pay for these speculative stocks. Caught up in the mix is the very under-covered Basilea Pharmaceutica (OTC:BPMUF), a small-cap Swiss biotech focused on antibiotics, antifugals, and oncology drugs. While the company does not yet have a drug approved in the U.S., key filings are close at hand for multiple drugs.
Investors should note that Basilea's U.S. ADRs are very illiquid. With less than 10 million shares outstanding, an average volume of about 110,000, and three analysts covering the company it is not as though the Swiss-listed...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|